Navigation Links
Let there be tissue-penetrating light: Scientists develop new nanoscale method to fight cancer
Date:2/28/2014

Researchers from UCLA's Jonsson Comprehensive Cancer Center have developed an innovative cancer-fighting technique in which custom-designed nanoparticles carry chemotherapy drugs directly to tumor cells and release their cargo when triggered by a two-photon laser in the infrared red wavelength.

The research findings by UCLA's Jeffrey Zink, a professor of chemistry and biochemistry, and Fuyu Tamanoi, a professor of microbiology, immunology and molecular genetics, and their colleagues were published online Feb. 20 in the journal Small and will appear in a later print edition.

Light-activated drug delivery holds promise for treating cancer because it give doctors control over precisely when and where in the body drugs are released. Delivering and releasing chemotherapy drugs so that they hit only tumor cells and not surrounding healthy tissues can greatly reduce treatment side effects and increase the drugs' cancer-killing effect. But the development of a drug-delivery system that responds to tissue-penetrating light has been a major challenge.

To address this, the teams of Tamanoi and Zink, which included scientists from the Jonsson Cancer Center's cancer nanotechnology and signal transduction and therapeutics programs, collaborated with Jean-Olivier Durand from France's University of Montpellier to develop a new type of nanoparticle that can absorb energy from tissue-penetrating light.

These new nanoparticles are equipped with thousands of pores, or tiny tubes, that can hold chemotherapy drugs. The ends of the pores are capped with nanovalves that keep the drugs in, like a cork in a bottle. The nanovalves contain special molecules that respond to energy from two-photon light exposure, which prompts the valves to open and release the drugs.

The operation of the nanoparticles was demonstrated in the laboratory using human breast cancer cells.

Because the effective range of the two-photon laser in the infrared red wavelength is 4 centimeters from the skin surface, this delivery system would work best for tumors within that range, which possibly include breast, stomach, colon and ovarian tumors, the researchers said.

In addition to their light sensitivity, the new nanoparticles are fluorescent and can be monitored in the body using molecular imaging techniques. This allows researchers to track the progress of the nanoparticle into the targeted cancer cell before light activation. The ability to track a targeted therapy in this way has been given the name "theranostics" a portmanteau of therapy and diagnostics in the scientific literature.

"We have a wonderful collaboration," Zink said. "When the Jonsson Comprehensive Cancer Center brings together totally diverse fields in this case, a physical chemist and a cell signaling scientist we can do things that neither one could do alone."

"Our collaboration with scientists at Charles Gerhardt Institute was important to the success of this two-photonactivated technique, which provides controls over drug delivery to allow local treatment that dramatically reduces side effects," said Tammanoi.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Dr. Carol Francis Radio Talk Show Discusses Sexual Abuse as Related to "Coach" Jerry Sandusky; Interview With Abuse Survivor Teresa Joyce, Author of "There's A Fine Line"
2. New findings by GW researcher break tanning misconceptions: There is no such thing as a safe tan
3. Are there gender differences in anti-HIV drug efficacy?
4. Theres an app for that: Apple iPod Touch helps adults with autism function in the workplace
5. Youth with autism gravitate toward STEM majors in college -- if they get there
6. Are there racial disparities in osteoporosis screening and treatment?
7. Predicting risk of arrhythmias and sudden cardiac death: Theres a computer model for that
8. Is there a period of increased vulnerability for repeat traumatic brain injury?
9. Why are there redheads? Birds might hold the clues
10. When It Comes to Spine Surgery, There Is No July Effect: Study
11. Theres room for improvement in womens heart disease awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
(Date:3/28/2017)... Wallingford, CT (PRWEB) , ... March 28, 2017 ... ... hemostatic devices, announces today that the University of Pittsburgh Medical Center (UPMC) will ... Central and Western Pennsylvania. , The program, developed in association with efforts by ...
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... March 29, 2017 On March 28, the U.S. Food ... patients with relapsing forms of multiple sclerosis (MS) and ... drug approved by the FDA for PPMS. Ocrevus is ... "Multiple sclerosis can have a profound ... , M.D., director of the Division of Neurology Products ...
Breaking Medicine Technology: